Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEO-DUR vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
300-600 mg orally twice daily
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2 and CYP3A4; also by N-acetylation and CYP2E1.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40-60% bound primarily to albumin. Lower in neonates, cirrhotics, and uremic patients.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Vd: 0.3-0.7 L/kg. Distributes into total body water; higher Vd in neonates (0.6-0.8 L/kg) and with acidosis.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: nearly 100% for immediate-release; extended-release formulations have 90-100% relative bioavailability compared to immediate-release.
Oral: 40-50%; Inhalation: 20-30%
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: reduce dose by 50%; Child-Pugh B or C: reduce dose by 75-80%
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Initial: 10-20 mg/kg/day orally divided q12h; titrate based on serum levels (therapeutic range 5-15 mcg/m L)
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lowest effective dose; monitor serum levels; decrease dose by 25-50% due to reduced clearance
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No
No FDA black box warning.
Risk of serious or fatal cardiovascular adverse events, including seizures and arrhythmias, especially at high doses.,Use with caution in patients with peptic ulcer, seizure disorders, cardiac disease, or hepatic impairment.,Monitor serum theophylline levels to avoid toxicity.,May exacerbate GERD.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation.,Concurrent use with ticlopidine or cimetidine (due to significant drug interactions)
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Food does not significantly affect absorption of sustained-release formulations; however, high-fat meals may slow absorption. Avoid large amounts of caffeine-containing foods/beverages. Charcoal-broiled foods may increase metabolism.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest a possible association with cardiovascular defects and oral clefts, though risk is low. Second and third trimesters: chronic high doses may cause fetal tachycardia and irritability; no structural teratogenicity reported. Overall, FDA Pregnancy Category C; risk vs benefit must be considered.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant exposure via milk is about 1-10% of maternal weight-adjusted dose. May cause irritability or insomnia in neonates. Use with caution, and monitor infant for signs of theophylline toxicity. Breastfeeding is generally considered acceptable if maternal levels are within therapeutic range and infant is observed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy increases theophylline clearance by approximately 30-50% due to hemodilution and increased hepatic metabolism. Dose may need to be increased by 30-50% to maintain therapeutic levels. Monitor serum concentrations frequently (every 1-2 weeks) and adjust accordingly. After delivery, clearance returns to prepregnancy levels within 2-4 weeks, requiring dose reduction to avoid toxicity.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theo-Dur (theophylline) has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Levels >20 mcg/m L increase toxicity risk. Monitor levels, especially with hepatic impairment, heart failure, or drugs that alter CYP1A2 metabolism (e.g., cimetidine, fluoroquinolones). Avoid use in active seizure disorders unless controlled. Use with caution in peptic ulcer disease.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Do not crush or chew sustained-release tablets; swallow whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, palpitations, seizures.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEO-DUR vs AEROLATE III, answered by our medical review team.
THEO-DUR is a Bronchodilator that works by Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEO-DUR and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEO-DUR is: 300-600 mg orally twice daily. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEO-DUR and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEO-DUR is classified as Category C. Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest . AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.